Cigna Group Q3 2026 earnings
Adjusted income from operations increased to $2.1 billion, or $7.98 per share, while shareholders' net income declined to $1.4 billion, or $5.47 per share, due to the absence of a prior-year gain on sale.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $73.68B | +5.6% | +2.9% | Ex. 99.1, income statement |
| EPS (GAAP) | $5.47 | -21.7% | -13.1% | Ex. 99.1, income statement |
| EPS (adjusted) | $7.98 | +1.9% | +2.6% | Ex. 99.1, income statement |
| Net income | $1.44B | -22.8% | -13.1% | Ex. 99.1, income statement |
| Adj. EBITDA | $2.10B | +0.4% | +2.4% | Ex. 99.1, income statement |
| Adj. EBITDA margin | 2.9% | -0.3 pp | +0.2 pp | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Evernorth Health Services | $63.77B | +5.5% | 86.5% | Adjusted revenues |
| Cigna Healthcare | $11.71B | +8.9% | 15.9% | Adjusted revenues |
Margins and costs
- Gross margin 2.9% (prior 3.2%, change -0.3 pp)
- Operating expenses $71.58B (+5.6% YoY)
- One-offs in the quarter Net investment losses $67M; Amortization of acquired intangible assets $449M; Special items $146M
- Effective tax rate 26.0% (prior-year 23.0%, year-to-date 26.0%)
- Non-GAAP bridge Adds back net investment gains/losses, amortization of acquired intangible assets, and special items; excludes equity method investment results.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Medical Care Ratio | 84.2% +/- 25 bps | 83.7% to 84.7% | N/A | Narrowed by 50 bps |
| Weighted average shares | 263.8M | 264.0M | 267.5M | -0.1M |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Adjusted Income from Operations, per share | at least $30.60 | at least $30.45 | +$0.15 |
| Evernorth Adjusted Income from Operations, Pre-Tax | at least $6,900 | at least $6,900 | 0 |
| Cigna Healthcare Adjusted Income from Operations, Pre-Tax | at least $4,600 | at least $4,550 | +$50 |
| Cigna Healthcare Medical Care Ratio | 84.2% +/- 25 bps | 83.7% to 84.7% | Narrowed by 50 bps |
What drove it
- Revenue story Total revenues grew 5.6% year-over-year to $73.68 billion, driven by Pharmacy revenues (+5.2% YoY) and Fees and other revenues (+3.4% YoY).
- EPS story Adjusted EPS increased 1.9% year-over-year to $7.98, supported by higher adjusted income from operations, while GAAP EPS declined due to the absence of a prior-year gain on sale.
- One-off check Net investment losses $67M, amortization of acquired intangible assets $449M, special items $146M.
The good
- Adjusted income from operations increased to $2.1 billion, or $7.98 per share
- Revenue grew 5.6% year-over-year to $73.68 billion
- Cigna Healthcare adjusted revenues grew 8.9% year-over-year to $11.71 billion
- Medical Care Ratio guidance narrowed to 84.2% +/- 25 bps
The bad
- Shareholders' net income declined 22.8% year-over-year to $1.44 billion
- Adjusted EBITDA margin decreased 0.3 percentage points year-over-year to 2.9%
- Adjusted EBITDA increased only 0.4% year-over-year to $2.10 billion
The ugly
- none
Open questions
- Impact of the planned exit from the Individual and Family Plans medical business as of January 1, 2027
- Specific drivers of the 0.3 pp decline in adjusted EBITDA margin
Full release
Cigna Group (CI) earnings release, November 5, 2026
INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
860-787-7968
Ralph.Giacobbe@TheCignaGroup.com
MEDIA CONTACT:
Justine Sessions
860-810-6523
Justine.Sessions@Evernorth.com
The Cigna Group Reports Strong
Third
Quarter
2026
Results, Raises 2026 Outlook
BLOOMFIELD, CT,
November 5, 2026 – Global health company The Cigna Group (NYSE: CI) today reported third quarter
2026 results, reflecting disciplined execution across its businesses and the strength of its capabilities to address increasingly complex health needs.
“Our vision for The Cigna Group’s next chapter of profitable growth is grounded in delivering greater value and personalized experiences for our customers, with three priorities
: driving core growth, leveraging our distinct capabilities, and executing with discipline,” said Brian Evanko, President and Chief Executive Officer of The Cigna
Group. “As we put our strategy in action, our strong third quarter results demonstrate how we are building on this momentum by making health care more affordable and personalized, while advancing Accelerate to One to drive productivity, reduce costs, and support sustained long-term earnings growth.”
Shareholders’ net income for third quarter
2026 was
$1.4 billion, or
$5.47 per share compared to
$1.9 billion, or
$6.98 per share for third quarter
2025, primarily reflecting the absence of an after-tax gain on sale recognized in third quarter 2025.
The Cigna Group’s adjusted income from operations¹ for third quarter
2026 was
$2.1 billion, or
$7.98 per share, compared with
$2.1 billion, or
$7.83 per shar e, for third quarter
2025.
A reconciliation of shareholders’ net income to adjusted income from operations¹ is provided on the following page and on Exhibit 1 of this earnings release.²
CONSOLIDATED HIGHLIGHTS
The following table includes highlights of results and reconciliations of total revenues to adjusted revenues³ and shareholders’ net income to adjusted income from operations¹
:³
CUSTOMER RELATIONSHIPS
The following table summarizes The Cigna Group’s medical customers and overall customer relationships:
Customer Relationships (in thousands):⁴
HIGHLIGHTS OF SEGMENT RESULTS
See Exhibit 1 for a reconciliation of adjusted income from operations¹ to shareholders’ net income.
Evernorth Health Services
This segment includes the Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.
Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.⁵
Cigna Healthcare
This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations.
In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.
Corporate and Other Operations
Corporate reflects interest expense, amounts not allocated to operating segments and includes intersegment eliminations. Other Operations is comprised of Corporate Owned Life Insurance (“COLI”), the Company’s run-off operations and other non-strategic businesses.⁶
2026
OUTLOOK²
The Cigna Group’s outlook for full year
2026 consolidated adjusted income from operations
1,2 is at least $30.60 per share². This outlook includes the impact of expected future share repurchases and anticipated
2026 dividends.⁷
The foregoing statements represent the Company’s current estimates of The Cigna Group’s
2026 consolidated and segment adjusted income from operations
Financial statements
Income Statement
: (in millions)
| Consolidated Financial Results (unaudited, dollars in millions): – Three Months Ended – September 30, – 2026 | Consolidated Financial Results (unaudited, dollars in millions): – Three Months Ended – September 30, – 2025 | Consolidated Financial Results (unaudited, dollars in millions): – Three Months Ended – June 30, – 2026 | Nine Months Ended – September 30, – 2026 | |
|---|---|---|---|---|
| Total Revenues | 73,683 | 69,748 | 71,668 | 213,845 |
| Net Investment Results from Equity Method Investments3 | 110 | -178 | -110 | 23 |
| Adjusted Revenues3 | 73,793 | 69,570 | 71,558 | 213,868 |
| Consolidated Earnings, net of taxes | ||||
| Shareholders’ Net Income | 1,442 | 1,868 | 1,660 | 4,756 |
| Net Investment Losses (Gains)1 | 67 | -43 | -55 | -221 |
| Amortization of Acquired Intangible Assets1 | 449 | 332 | 296 | 1,060 |
| Special Items1 | 146 | -61 | 153 | 621 |
| Adjusted Income from Operations1 | 2,104 | 2,096 | 2,054 | 6,216 |
| Shareholders’ Net Income, per share | 5.47 | 6.98 | 6.29 | 18.02 |
| Adjusted Income from Operations1, per share | 7.98 | 7.83 | 7.78 | 23.55 |
Income Statement
In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027. (in millions)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Three Months Ended – June 30, – 2026 | Nine Months Ended – September 30, – 2026 | |
|---|---|---|---|---|
| Financial Results (dollars in millions): | ||||
| Adjusted Revenues3,7 | 11,708 | 10,755 | 11,728 | 34,913 |
| Adjusted Income from Operations, Pre-Tax1 | 1,193 | 1,038 | 1,276 | 3,983 |
| Margin, Pre-Tax6 | 10.2 | 9.7 | 10.9 | 11.4 |
Income Statement
dividends. (dollars in millions, except where noted and per share amounts)
| 2026 Consolidated Metrics – Projection for Full Year Ending December 31, 2026 | 2026 Consolidated Metrics – Change from Prior Projection | |
|---|---|---|
| Adjusted Income from Operations, per share1,2 | at least $30.60 | 0.15 |
| Evernorth Adjusted Income from Operations, Pre-Tax1,2 | at least $6,900 | |
| Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2 | at least $4,600 | 50 |
| Cigna Healthcare Medical Care Ratio2,4 | 84.2% +/- 25 bps | Narrowed by 50 bps |
Income Statement
Three Months Ended September 30, (Dollars in millions, except per share amounts)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | Three Months Ended June 30, – 2026 | |
|---|---|---|---|---|---|
| REVENUES | |||||
| Pharmacy revenues | 58,982 | 56,054 | 170,191 | 158,336 | 57,172 |
| Premiums | 9,885 | 9,081 | 29,556 | 30,973 | 9,859 |
| Fees and other revenues | 4,529 | 4,380 | 13,337 | 12,412 | 4,365 |
| Net investment income | 287 | 233 | 761 | 707 | 272 |
| Total revenues | 73,683 | 69,748 | 213,845 | 202,428 | 71,668 |
| Net investment results from certain equity method investments | 110 | -178 | 23 | -272 | -110 |
| Adjusted revenues (1) | 73,793 | 69,570 | 213,868 | 202,156 | 71,558 |
| Shareholders’ net income | 1,442 | 1,868 | 4,756 | 4,723 | 1,660 |
| Pre-tax adjusted income (loss) from operations by segment | |||||
| Evernorth Health Services | 1,829 | 1,903 | 4,958 | 5,033 | 1,663 |
| Cigna Healthcare | 1,193 | 1,038 | 3,983 | 3,419 | 1,276 |
| Corporate and Other Operations | -372 | -363 | -1,138 | -1,131 | -389 |
| Adjusted income tax expense | -546 | -482 | -1,587 | -1,455 | -496 |
| Consolidated after-tax adjusted income from operations | 2,104 | 2,096 | 6,216 | 5,866 | 2,054 |
| Weighted average shares (in thousands) | 263,788 | 267,530 | 263,923 | 269,527 | 263,962 |
| Common shares outstanding (in thousands) | 263,403 | 267,072 | 264,154 | ||
| SHAREHOLDERS’ EQUITY at September 30, | 43,383 | 41,805 | |||
| SHAREHOLDERS’ EQUITY PER SHARE at September 30, | 164.7 | 156.53 | |||
Income Statement (in millions)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Three Months Ended – June 30, – 2026 | Nine Months Ended – September 30, – 2026 | |
|---|---|---|---|---|
| Total Adjusted Revenues | ||||
| Pharmacy Benefit Services | 37,276 | 34,091 | 34,496 | 104,774 |
| Specialty and Care Services | 26,498 | 26,300 | 26,972 | 78,910 |
| Adjusted Revenues3 | 63,774 | 60,391 | 61,468 | 183,684 |
| Adjusted Income from Operations, Pre-Tax | ||||
| Pharmacy Benefit Services | 765 | 975 | 609 | 1,768 |
| Specialty and Care Services | 1,064 | 928 | 1,054 | 3,190 |
| Adjusted Income from Operations, Pre-Tax1 | 1,829 | 1,903 | 1,663 | 4,958 |
| Margin, Pre-Tax6 | 2.9 | 3.2 | 2.7 | 2.7 |
1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.
This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations section ( https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review third quarter
2026 results and discuss full year
2026 outlook beginning today... (truncated)e Cigna Group’s website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx.
The call-in numbers for the conference call are as follows:
Live Call
(888) 566-1889
(Domestic)
(773) 799-3989
(International)
Passcode: 11052026
Replay
(866) 405-7290
(Domestic)
(203) 369-0603
(International)
It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services,
Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has approximately 180 million customer relationships around the world. Learn more at thecignagroup.com.
Notes:⁸
The Company’s outlook excludes the potential effects of any other business combinations that may occur after the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated
2026 dividends.
The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.⁹¹⁰
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected outlook for 2026 (including adjusted income from operations, including on a per share and segment basis, and medical care ratio); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives, including our modernization and productivity initiatives; our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as
“believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other... (truncated)privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.
(1)
Adjusted revenues is defined as total revenues excluding the following adjustments: special items and The Cigna
Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our businesses.
(2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.
(3) Adjusted income (loss) from operations is defined as shareholders’ net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.